Inozyme Pharma, Inc. (INZY) has 27 open-market insider trades by 19 insiders since 2020. The most active filer is Robert Lorne Hopfner, Director.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Robert Lorne Hopfner | Dir | — | 6 | $22.0M | 2025-07-01 |
| Novo Holdings A/S | 10% Owner | — | 2 | $13.9M | 2021-01-28 |
| Juliet Tammenoms Bakker | 10% Owner | — | 1 | $10.0M | 2020-07-28 |
| Rock Springs Capital LLC | 10% Owner | — | 1 | $9.6M | 2020-07-28 |
| Peter Kolchinsky | 10% Owner | — | 1 | $9.6M | 2020-07-28 |
| James Healy | 10% Owner | — | 1 | $7.0M | 2020-07-28 |
| Longitude Capital Partners III, LLC | 10% Owner | — | 1 | $5.0M | 2022-04-19 |
| Mohamad Makhzoumi | 10% Owner | — | 1 | $4.0M | 2020-07-28 |
| Forest Baskett | 10% Owner | — | 1 | $4.0M | 2020-07-28 |
| Scott D. Sandell | 10% Owner | — | 1 | $4.0M | 2020-07-28 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Douglas A. Treco | Chairman | Sell | $8K | 2025-04-02 |
| Douglas A. Treco | CEO | Sell | $104K | 2024-04-02 |
| Robert Lorne Hopfner | Director | Buy | $4.6M | 2023-08-01 |
| Pivotal bioVenture Partners Fund I, L.P. | Director | Buy | $571K | 2023-08-01 |
| Robert Lorne Hopfner | Director | Buy | $5.7M | 2023-05-11 |
| Robert Lorne Hopfner | Director | Buy | $3.1M |
Companies that share insiders with INZY, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| 2023-03-29 |
| Robert Lorne Hopfner | Director | Buy | $1.7M | 2023-03-27 |
| Henric Bjorn Bjarke | COO & SVP | Buy | $30K | 2022-12-15 |
| Henric Bjorn Bjarke | COO & VP | Buy | $100K | 2022-04-19 |
| Longitude Capital Partners III, LLC | 10% Owner | Buy | $5.0M | 2022-04-19 |
| Axel Bolte | CEO | Buy | $500K | 2022-04-19 |
| Robert Lorne Hopfner | Director | Buy | $3.9M | 2022-04-19 |
| Novo Holdings A/S | 10% Owner | Sell | $7.9M | 2021-01-28 |
| Juliet Tammenoms Bakker | 10% Owner | Buy | $10.0M | 2020-07-28 |
| Peter W. Sonsini | 10% Owner | Buy | $4.0M | 2020-07-28 |